Table 1.
Baseline characteristics of patients in the cyclophosphamide (CYC) and mycophenolate mofetil (MMF) groups
| Parameter* | CYC (n = 25) | MMF (n = 25) |
|---|---|---|
| Age at recruitment (years) | 31.4 ± 6.4 | 28.4 ± 4.4 |
| Age at diagnosis (years) | 28.4 ± 6.1 | 24.1 ± 4.4 |
| Duration of disease from diagnosis (years) | 3 ± 2.9 | 4.3 ± 4 |
| SLEDAI | 7.2 ± 2.5 | 5.8 ± 3.4 |
| Marital status | ||
| Unmarried | 6 (24%) | 8 (32%) |
| Completed family | 13 (52%) | 6 (24%) |
| Gestational history | ||
| Median number of successful pregnancies | 1 | 1 |
| Median number of abortions | 0 | 0 |
| Menstrual cycles at recruitment | ||
| Regular | 24 (96%) | 24 (96%) |
| Oligomenorrhoea | 1 (4%) | 1 (4%) |
| ANA positivity | 25 (100%) | 25 (100%) |
| dsDNA positivity | 21 (84%) | 23 (92%) |
| Hypocomplementaemia | 17 (68%) | 13 (52%) |
| Creatinine (mg/dl) | 1.38 ± 0.92 | 0.93 ± 0.56 |
| TSH (mIU/l) | 3.37 ± 1.95 | 2.69 ± 2.24 |
| Testosterone (nmol/l) | 0.29 ± 0.35 | 0.47 ± 0.71 |
| Prolactin (ng/ml) | 18.26 ± 7.60 | 23.31 ± 21.02 |
| Kidney biopsy class | ||
| Class II | 1 (5%) | 1 (4.5%) |
| Class III | 2 (10%) | 5 (23.7%) |
| Class IV | 12 (60%) | 6 (27.3%) |
| Class III + V | 0 | 1 (4.5%) |
| Class IV + V | 5 (25%) | 2 (9%) |
| Class V | 0 | 7 (32%) |
CYC cyclophosphamide, MMF mycophenolate mofetil, SLEDAI Systemic Lupus Erythematosus Disease Activity Index, ANA antinuclear antibodies, dsDNA anti-double-stranded deoxyribonucleic acid antibodies, TSH thyroid-stimulating hormone
*Reported as mean ± SD or n (%)